英派药业-B(07630)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

07630 英派药业-B

未开盘 07-06 16:08:30

20.500

+0.380

+1.89%

最高21.060	最低19.420	成交量38.68万
今开20.140	昨收20.120	日振幅8.15%
总市值57.90亿	流通市值57.90亿	总股本2.82亿
成交额788.42万	换手率0.14%	流通股本2.82亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"07630","market":"HK","secType":"STK","nameCN":"英派药业-B","latestPrice":20.5,"timestamp":1783325310716,"preClose":20.12,"halted":0,"volume":386800,"delay":0,"changeRate":0.018886679920477087,"floatShares":282461530,"shares":282461530,"eps":-1.440772,"marketStatus":"未开盘","change":0.38,"latestTime":"07-06 16:08:30","open":20.14,"high":21.06,"low":19.42,"amount":7884198,"amplitude":0.081511,"askPrice":20.5,"askSize":3200,"bidPrice":20.08,"bidSize":1000,"shortable":0,"etf":0,"ttmEps":-1.16,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1783387800000},"marketStatusCode":0,"adr":0,"listingDate":1778601600000,"exchange":"SEHK","adjPreClose":20.12,"openAndCloseTimeList":[[1783301400000,1783310400000],[1783314000000,1783324800000]],"volumeRatio":0.4612625331829953,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/07630","defaultTab":"news","newsList":[{"id":"2649702626","title":"Tencent Holdings Limited增持英派药业-B(07630)35万股 每股作价约36.17港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2649702626","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649702626?lang=zh_cn&edition=full","pubTime":"2026-07-06 19:36","pubTimestamp":1783337776,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新数据显示，6月30日，Tencent Holdings Limited增持英派药业-B(07630)35万股，每股作价36.1719港元，总金额约为1266.02万港元。增持后最新持股数目约为1988.05万股，持股比例为7.04%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1463687.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["07630","EWH","BK4588","BK1161","BK4585","BK4504","BK4550","EDZ","IEMG","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649626700","title":"Tencent Holdings Limited增持英派药业-B(07630.HK)35万股 每股作价约36.17港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2649626700","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649626700?lang=zh_cn&edition=full","pubTime":"2026-07-06 19:36","pubTimestamp":1783337776,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1117782722","title":"英派药业-B6月股份变动月报：注册股本增至282,461,530股","url":"https://stock-news.laohu8.com/highlight/detail?id=1117782722","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1117782722?lang=zh_cn&edition=full","pubTime":"2026-07-06 17:11","pubTimestamp":1783329061,"startTime":"0","endTime":"0","summary":"南京英派药业股份有限公司（英派药业-B, 07630）于2026年7月6日披露了截至2026年6月30日的股份变动月报。报告期内，公司完成了超额配股权益的行使，新发行并配发6,296,400股H股，使注册股本由276,165,130股增至282,461,530股。\n本月无股份购回、注销及库藏股变动，也未披露任何新的股份期权或股权激励计划。公司表示已遵守香港联合交易所有限公司《上市规则》及相关法律法规要求。公告由执行董事兼首席执行官蔡遂雄签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647453054","title":"55家公司港股通新贵即将喜迎北水流入 入通门槛或已抬升至102.67亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2647453054","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647453054?lang=zh_cn&edition=full","pubTime":"2026-07-01 10:09","pubTimestamp":1782871774,"startTime":"0","endTime":"0","summary":"核心规则：市值门槛动态调整截至2026年6月30日，港股通实际纳入门槛已升至102.67亿，剔除门槛达66.89亿。这一指标直接决定了个股在指数中的权重与港股通资格。对于不同上市时长的公司，要求有所不同：对于上市公司而言，维持日均万五左右的换手率是保住港股通资格的关键。数据截止日为每年的6月30日和12月31日，这也是上市公司\"冲关\"港股通的关键时间窗口。","market":"hk","thumbnail":"https://static.tigerbbs.com/0cf777090175126e4590c3b8afdfe41e","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/0cf777090175126e4590c3b8afdfe41e"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1461288.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["00600","01651","03355","01286","00376","03277","01133","02616","02632","06658","02553","BK4588","01779","03887","01191","06675","02335","01866","01609","03310","01672","01956","02672","00340","06656","02723","09630","06636","00068","02142","03388","02729","01392","06938","06106","01236","02526","02726","07666","01511","02272","03625","00100","07688","09637","01081","01021","03661","06872","02696","00412","02670","07630","01440","01879","BK4585","00863"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2647770353","title":"股东施毅增持英派药业-B(07630)2.00万股 每股作价约35.94港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2647770353","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647770353?lang=zh_cn&edition=full","pubTime":"2026-06-29 21:30","pubTimestamp":1782739825,"startTime":"0","endTime":"0","summary":"香港联交所最新数据显示，6月24日，股东施毅增持英派药业-B(07630)2万股，每股作价35.9388港元，总金额约为71.88万港元。","market":"sh","thumbnail":"https://img.zhitongcaijing.com/image/20260629/20260629213043_51705.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260629/20260629213043_51705.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1460671.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["EWH","BK1161","07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106328124","title":"英派药业-B：6月10日因超额配股权行使发行629.64万股H股，涉资约1.27亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1106328124","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1106328124?lang=zh_cn&edition=full","pubTime":"2026-06-11 06:12","pubTimestamp":1781129528,"startTime":"0","endTime":"0","summary":"2026年6月11日，南京英派药业股份有限公司（英派药业-B，股票代码：07630）发布公告，披露于2026年6月10日因超额配股权获悉数行使，新增发行并配发6,296,400股H股，占发行前已发行股本约2.3%。每股发行价为20.1港元，合计涉资约1.27亿港元。\n本次发行完成后，公司已发行股本由276,165,130股增至282,461,530股。公司确认本次发行已遵循香港联交所证券上市规则及相关法律法规规定，并获得董事会正式授权。上述公告由公司执行董事兼首席执行官蔡遂雄签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"英派药业-B：6月10日因超额配股权行使发行629.64万股H股，涉资约1.27亿港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642471572","title":"英派药业-B(07630)因超额配股权获行使而发行629.64万股H股","url":"https://stock-news.laohu8.com/highlight/detail?id=2642471572","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642471572?lang=zh_cn&edition=full","pubTime":"2026-06-11 06:10","pubTimestamp":1781129453,"startTime":"0","endTime":"0","summary":"智通财经APP讯，英派药业-B(07630)发布公告，于2026年6月10日因超额配股权获悉数行使而发行及配发629.64万股H股股份。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1452889.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["07630","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641107217","title":"英派药业-B(07630)：悉数行使超额配股权、稳定价格行动及稳定价格期结束","url":"https://stock-news.laohu8.com/highlight/detail?id=2641107217","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641107217?lang=zh_cn&edition=full","pubTime":"2026-06-08 16:53","pubTimestamp":1780908808,"startTime":"0","endTime":"0","summary":"智通财经APP讯，英派药业-B 发布公告，有关全球发售的稳定价格期于2026年6月7日(星期日)结束。于稳定价格期，稳定价格操作人并无出于稳定价格的目的在市场上购入或出售任何H股。紧随超额配股权获悉数行使及稳定价格期结束后，本公司将继续遵守上市规则第19A.28B条的公众持股量规定。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1451397.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["07630","BK1161"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2641760148","title":"英派药业-B(07630)：超额配股权获悉数行使","url":"https://stock-news.laohu8.com/highlight/detail?id=2641760148","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641760148?lang=zh_cn&edition=full","pubTime":"2026-06-05 20:54","pubTimestamp":1780664056,"startTime":"0","endTime":"0","summary":"智通财经APP讯，英派药业-B(07630)公布，招股章程所述超额配股权已于2026年6月5日(星期五)获整体协调人(为其本身及代表国际包销商)悉数行使，涉及合共629.64万股H股，占于任何超额配股权获行使前全球发售项下初步可供认购的发售股份总数约15%。因超额配股权获行使而将予发行的H股(“超额配发股份”)将由本公司按每股H股 20.10港元发行及配发。超额配发股份将用于加快向同意延迟交付其根据全球发售认购的相关H股的承配人交付部分H股。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1450968.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["07630","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193760729","title":"英派药业-B5月股份变动月报：股本保持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1193760729","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1193760729?lang=zh_cn&edition=full","pubTime":"2026-06-04 18:11","pubTimestamp":1780567895,"startTime":"0","endTime":"0","summary":"南京英派药业股份有限公司于2026年6月4日发布截至2026年5月31日止的股份变动月报。公告显示，公司法定/注册股本在报告期内无变化，截至2026年5月31日止的法定/注册股本数为人民币276,165,130元；普通股H股的已发行股本维持在276,165,130股，未发生任何新增发行、回购或转换注销。公司5月内也未发生任何库存股变动，库存股份数仍为0股。根据本次月报，英派药业-B的股本结构自上市以来保持稳定。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1130218577","title":"英派药业-B授予董事股份购回授权，规模达已发行股本一成","url":"https://stock-news.laohu8.com/highlight/detail?id=1130218577","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1130218577?lang=zh_cn&edition=full","pubTime":"2026-06-03 18:36","pubTimestamp":1780483018,"startTime":"0","endTime":"0","summary":"英派药业-B6月3日发布公告，董事会已获一般性授权，可在香港联合交易所有限公司按不超过公司已发行H股总数10%的规模进行股份购回。现有发行股本约2.76亿股H股，授权范围最高可达约2761.65万股，购回事宜尚需于2026年6月25日召开的年度股东大会上审议并生效。根据公告，英派药业-B上市后，于2026年5月13日至6月初期间，H股最高价为每股47.98港元，最低为28.20港元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"英派药业-B授予董事股份购回授权，规模达已发行股本一成","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640981904","title":"英派药业-B(07630)：IMP1734于2026年ASCO年会公布I/II期临床数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2640981904","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640981904?lang=zh_cn&edition=full","pubTime":"2026-06-01 08:37","pubTimestamp":1780274251,"startTime":"0","endTime":"0","summary":"智通财经APP讯，英派药业-B(07630)发布公告，于2026年5月29日至6月2日在美国芝加哥举办的2026年美国临床肿瘤学会(ASCO)年会上，以壁报形式发布高选择性PARP1抑制剂IMP1734(亦称为EIK1003)的最新I/II期临床数据。该壁报(摘要编号：#3102)展示了IMP1734单药治疗及联合紫杉醇治疗晚期实体瘤的安全性与初步有效性数据。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1448253.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["07630","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121551346","title":"异动解读 | 英派药业-B盘中大涨15.59%，受技术反弹、内部增持及核心产品纳入医保等多重利好推动","url":"https://stock-news.laohu8.com/highlight/detail?id=1121551346","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1121551346?lang=zh_cn&edition=full","pubTime":"2026-05-22 11:15","pubTimestamp":1779419700,"startTime":"0","endTime":"0","summary":"英派药业-B今日盘中大涨15.59%，引起了市场的广泛关注。消息面上，此次上涨可能受到多重因素驱动。其次，公司关联方在上市日进行了大额增持，释放了内部对公司前景的信心信号。更重要的是，公司的核心产品塞纳帕利已被纳入国家医保目录并从今年开始执行医保价格，这有望显著推动其营收放量。英派药业是一家专注于基于合成致死机制的精准抗癌疗法研发的生物技术公司，目前已进入商业化阶段。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103271327","title":"异动解读｜英派药业-B盘中上涨13.17%，上市初期获利回吐后快速反弹获资金回补","url":"https://stock-news.laohu8.com/highlight/detail?id=1103271327","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1103271327?lang=zh_cn&edition=full","pubTime":"2026-05-22 11:13","pubTimestamp":1779419602,"startTime":"0","endTime":"0","summary":"5月22日，英派药业-B盘中上涨13.17%，报35.58港元，成交额871.6万港元。消息面上，公司于5月13日以每股20.10港元登陆港交所，首日大涨108.26%，此后经历获利回吐股价自高点回落超15%，昨日一度下跌逾5%后今日迎来强势反弹。英派药业是一家专注于基于合成致死机制的精准抗癌疗法研发的商业化阶段生物技术公司，核心产品塞纳帕利已在中国获批上市，产品管线涵盖PARP1/2、PARP1、ATR、WEE1等多个靶点。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161371010","title":"异动解读 | 英派药业-B盘中大跌5.18%，上市后冲高回落现获利回吐压力","url":"https://stock-news.laohu8.com/highlight/detail?id=1161371010","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1161371010?lang=zh_cn&edition=full","pubTime":"2026-05-21 10:31","pubTimestamp":1779330713,"startTime":"0","endTime":"0","summary":"英派药业-B(07630)今日盘中股价大幅下挫5.18%，引发市场关注。消息面上，公司近期登陆港交所后股价经历了大幅上涨，自高点回落幅度已超过15%，短期获利盘兑现压力开始显现。此外，公司目前仍处于亏损阶段，2025年净亏损约2.96亿元，而营收仅为3825万元，尚无法覆盖高强度的研发投入，基本面对当前较高估值的支撑力度有限，可能也是股价承压的因素之一。英派药业是一家基于合成致死机制的精准抗癌疗法企业，其核心产品塞纳帕利已在中国获批上市并纳入医保目录。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118559761","title":"异动解读｜英派药业-B盘中下跌5.77%，上市后冲高回落或现获利回吐压力","url":"https://stock-news.laohu8.com/highlight/detail?id=1118559761","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1118559761?lang=zh_cn&edition=full","pubTime":"2026-05-21 10:30","pubTimestamp":1779330603,"startTime":"0","endTime":"0","summary":"5月21日，英派药业-B盘中下跌5.77%，报35.28港元，成交额511.1万港元。消息面上，公司于5月13日以每股20.10港元定价登陆港交所，首日收报41.86港元，较招股价涨108.26%，此后连续多日维持高位震荡。经历上市后大幅上涨，股价自高点回落幅度已超15%，短期获利盘兑现压力显现。值得关注的是，公司仍处亏损阶段，2025年净亏损约2.96亿元，营收仅3825万元，尚无法覆盖高强度研发投入，基本面对高估值的支撑力度有限。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636835929","title":"港股异动 | 英派药业-B(07630)尾盘涨近4% 核心产品塞纳帕利去年12月已纳入医保","url":"https://stock-news.laohu8.com/highlight/detail?id=2636835929","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636835929?lang=zh_cn&edition=full","pubTime":"2026-05-19 15:49","pubTimestamp":1779176941,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，英派药业-B尾盘涨近4%，截至发稿，涨3.93%，报39.66港元，成交额1382.25万港元。国投证券国际指出，英派药业为国内合成致死赛道的制药企业，已与Eikon、华东医药达成战略合作，核心产品塞纳帕利已纳入医保，短期可关注其医保放量和EMA上市申请审批进度，长期看其他管线临床数据读出及商业化进展。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1443384.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VXUS","BK4588","07630","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145155707","title":"异动解读 | 英派药业-B盘中大涨6.95%，上市表现强劲、核心产品纳入医保及创新管线潜力受关注","url":"https://stock-news.laohu8.com/highlight/detail?id=1145155707","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1145155707?lang=zh_cn&edition=full","pubTime":"2026-05-15 09:41","pubTimestamp":1778809313,"startTime":"0","endTime":"0","summary":"英派药业-B今日盘中大涨6.95%，引起了市场的广泛关注。消息面上，公司于5月13日以每股20.10港元定价登陆港交所，香港公开发售获2282.4倍超额认购，一手中签率仅1.5%，首日收报41.86港元，较招股价涨108.26%，上市后市场情绪延续强势。此外，公司核心产品塞纳帕利已于2025年1月获批用于卵巢癌一线维持治疗，并于2025年12月纳入国家医保目录，自今年1月起正式执行医保价格，有望推动营收持续放量。公司在研管线IMP32为全球首个靶向CEACAM5的双载荷ADC，具备First-in-Class地位，展示了公司的研发实力和未来增长潜力，进一步增强了投资者信心。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635201905","title":"【新股IPO】英派药业(07630)首挂收报41.86港元 较招股价高108.26%","url":"https://stock-news.laohu8.com/highlight/detail?id=2635201905","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635201905?lang=zh_cn&edition=full","pubTime":"2026-05-13 16:16","pubTimestamp":1778660200,"startTime":"0","endTime":"0","summary":"金吾财讯 | 英派药业(07630)首挂收报41.86港元，较招股价高108.26%，全日成交1513.5万股，成交额5.44亿港元，不计手续费，每手200股，账面赚4352港元。该股早盘开报35.5港元，较招股价高76.62%，全日最低33.1港元，最高见45.8港元。最新总市值115.6亿港元。","market":"fut","thumbnail":"https://static.szfiu.com/news/20220324/YjI0MWRiZGM3ZjA2MTU3MTE2NDgwOTA4MzEyNTY=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20220324/YjI0MWRiZGM3ZjA2MTU3MTE2NDgwOTA4MzEyNTY=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1981283","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630","EWH","SPCX","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198038909","title":"港股异动 | 英派药业-B首日高开高走，股价涨幅扩大至117%","url":"https://stock-news.laohu8.com/highlight/detail?id=1198038909","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1198038909?lang=zh_cn&edition=full","pubTime":"2026-05-13 12:00","pubTimestamp":1778644826,"startTime":"0","endTime":"0","summary":"5月13日，$英派药业-B$首日高开高走，截止发稿股价涨超117%。核心产品派舒宁已于2025年1月获得中国国家药品监督管理局批准上市，并于2025年12月纳入国家基本医保目录。此外，英派的IMP32是全球首个、且目前唯一靶向CEACAM5的TOP1i+ATRi双载荷ADC，具备明确的First-in-Class地位。随着塞纳帕利自 2026 年1月1日起正式执行国家医保目录价格，叠加公司在研管线持续推进、有望持续兑现更多里程碑收益，有望实现营收规模持续快速放量增长。","market":"hk","thumbnail":"https://static.tigerbbs.com/3153c88188d79bb8182b93c4fdd43636","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/3153c88188d79bb8182b93c4fdd43636"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.impacttherapeutics.com","stockEarnings":[{"period":"1week","weight":-0.4459},{"period":"1month","weight":-0.4462},{"period":"3month","weight":0.0199},{"period":"ytd","weight":0.0199}],"compareEarnings":[{"period":"1week","weight":0.0256},{"period":"1month","weight":-0.0539},{"period":"3month","weight":-0.0597},{"period":"6month","weight":-0.1074},{"period":"1year","weight":-0.0125},{"period":"ytd","weight":-0.0786}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"南京英派药业股份有限公司是一家主要从事生物技术研发和商业化的中国公司。该公司处于商业化阶段。该公司致力于在全球范围内推进基于合成致死（SL）机制的精准抗癌疗法。该公司自主研发的核心产品塞纳帕利已在中国获批上市，作为卵巢癌（OC）一线维持疗法。该公司正在研发的产品管线包PARP1/2、PARP1、ATR、WEE1、PKMYT1/WEE1、DHX9、ATM、USP1及CHK1/2等。","exchange":"SEHK","name":"英派药业-B","nameEN":"IMPACT THERAP-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"英派药业-B(07630)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供英派药业-B(07630)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"英派药业-B,07630,英派药业-B股票,英派药业-B股票老虎,英派药业-B股票老虎国际,英派药业-B行情,英派药业-B股票行情,英派药业-B股价,英派药业-B股市,英派药业-B股票价格,英派药业-B股票交易,英派药业-B股票购买,英派药业-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"英派药业-B(07630)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供英派药业-B(07630)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}